R&D
A global pioneer in the development of new drugs
Our Medicines
SK Biopharmaceuticals and its U.S. subsidiary SK Life Science independently developed XCOPRI® (cenobamate) from inception through to the FDA approval.
SK Biopharmaceuticals also discovered and licensed-out the FDA and EMA-approved treatment
SUNOSI® (solriamfetol)* after completing phase 1 clinical trials.
SUNOSI® (solriamfetol)* after completing phase 1 clinical trials.
*Jazz Pharmaceuticals holds rights to develop and commercialize solriamfetol worldwide, excluding certain jurisdictions in Asia, while SK Biopharmaceuticals maintains rights for the 12 Asian markets.
You are about to leave this website. This link will take you to a site maintained by a third party. SK Biopharmaceuticals is not responsible for its contents.